Evaxion A/S sold 681,268 American Depositary Shares (ADSs) at an average price of USD $3.1987 per ADS through its at-the-market offering with Jones Trading Institutional Services LLC. Net proceeds from the transaction totaled $2,113,767 after deducting fees and expenses. The company registered a share capital increase of nominal DKK 8,515,850 with the Danish Business Authority, effective August 24, 2026, bringing total nominal share capital to DKK 112,768,539. Articles of Association were amended to reflect these changes. Evaxion A/S operates in the biotechnology industry, focusing on developing cancer vaccines.

Evaxion A/S reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to $4.8 million in the same period last year. Cash and cash equivalents stood at $14.0 million as of June 30, 2026, providing a runway into the second half of 2027. The company announced business updates including upcoming presentations of three-year clinical data for EVX-01 at ESMO Congress 2026 and new preclinical data for EVX-04 and EVX-V1. Evaxion A/S is a clinical-stage biotechnology company developing AI-powered vaccines for cancer and infectious diseases.

Evaxion A/S filed its unaudited condensed consolidated interim financial results for the six months ended June 30, 2026. The company reported a net loss of $7.4 million, compared to a $6.4 million loss in the prior year period. Research and development expenses increased slightly to $4.6 million from $4.3 million, while general and administrative expenses decreased to $3.0 million from $3.9 million due to lower capital market transaction costs. Cash and cash equivalents stood at $14.0 million as of June 30, 2026, down from $23.2 million at year-end 2025. Management stated that current liquidity is sufficient to fund operations into the second half of 2027. The company operates in the biopharmaceutical industry, developing personalized and off-the-shelf cancer vaccines using its AI-Immunology platform.

Evaxion A/S announced the expansion of its R&D pipeline with EVX-05, an AI-designed off-the-shelf therapeutic vaccine for glioblastoma developed in collaboration with Duke University School of Medicine. The company discontinued the EVX-03 program as part of portfolio management and confirmed that costs for EVX-05 are covered by existing budgets, maintaining its cash runway into the second half of 2027. Evaxion is a clinical-stage TechBio company specializing in developing AI-powered cancer vaccines.